TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to aneurysm detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ApoJ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ≥ 25% improvement in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 50% improvement in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FF-MALE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hourly consumption of epidural LA anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete analgesia (NRPS ≤1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower NRPS in the first hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RT-PCR negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement for high-dose opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to switch medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engage in information-seeking behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement between assessors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater and test-retest reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Mass (LVM) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Mass Index (LVM index) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Care seeking for sexual violence (SV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-TSST anger ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute G1-G2 gastrointestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Acute G1-G2 genitourinary toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Total effective rate of TCM symptom pattern score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevention of declines in adolescent physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DVAS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean lymphocytes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric mean titers (GMTs) of HAI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers (GMTs) of MN antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Public stigma towards decedent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Harm reduction support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total MSQ score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total MIDAS score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proptosis change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diplopia response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ammonia levels in patients with hyperammonemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of IMD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic efficiency of the model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional independence (modified Rankin Scale score 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of AO (Abdominal Obesity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in brain amyloid plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting glucagon concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Steady-state glucagon concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AGR (Area under the curve for glucagon)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cannabis negative urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal color and swelling degree scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphocyte loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in ALSFRS‐R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VC (Vital Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barriers to implementation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: decision making and preferences
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: satisfaction on the CSQ‐8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: global satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: visit length
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of WKF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of death associated with WKF
Endpoint domain: Mortality/survival
Primary endpoint: Risk of subsequent cardiovascular events associated with WKF
Endpoint domain: Mortality/survival
Primary endpoint: Nasal symptoms (rhinorrhea, nasal itching, sneezing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSS-I score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal 25(OH)D at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in primary (amorphous) CPP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in secondary (crystalline) CPP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased levels of interleukin-6 (IL-6) and IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of intradialytic hypotension (IH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total malnutrition inflammation score (MIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cachexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction factors against murine norovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: abstinent cotinine samples submitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of CRPS
Endpoint domain: Mortality/survival
Primary endpoint: mean progression-free survival (mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: mean overall survival (mOS)
Endpoint domain: Mortality/survival
Primary endpoint: Herbal medicine use prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: net drop of liver iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net reduction in serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in WMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean RMDQ score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation/perfusion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall satisfaction of the 3D printed models
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: anxiety decrease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression-Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social and Occupational Functioning Assessment Scale (SOFAS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean ATP level after HLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of duodenoscopes with ATP≥40 RLU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BC rate after manual cleaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BASDAI 50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASDAS <1.3 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: adjusted drop-out rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient expectation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Requirement for noradrenaline administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: biochemical measures (C-reactive protein, tumor necrosis factor-α, IL-2, IL-4, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean central Vault
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior chamber angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety index
Endpoint domain: Adverse events/effects
Primary endpoint: hyperglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cortisol reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dynamic mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total body lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Favorable neurologic outcome
Endpoint domain: Mortality/survival
Primary endpoint: cervical lordosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-perceived cognitive capacity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stable Disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Rate at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary 6‐sulfatoxymelatonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of high-grade cervical lesions (CIN2+ and CIN3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parental injury preventive practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Usability Scale (SUS) rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically significant depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportions of participants experiencing adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Memory score on Stroke Impact Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication score on Stroke Impact Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local efficiency of the IMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: coupling effect of CMC→IMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hemispheric autonomy index of IPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early response with no residual tumor detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 3 dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: paid employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Phase angle values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of CV death, myocardial infarction or repeat target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: MR ≤2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IOL decentration at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neodymium‐doped yttrium aluminum garnet posterior capsulotomy rates for PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Best corrected visual acuity (BCVA) at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to fragility fracture or death
Endpoint domain: Mortality/survival
Primary endpoint: ICER per fracture-free year of survival
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Invasive mechanical ventilation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBS (Prosthetic Space Disinfection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in subjective general psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of PTT-BP correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ruxolitinib plasma concentrations at steady-state (Css)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in disease attack risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of worsening from baseline in Expanded Disability Status Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative total active MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ICU admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in PROs (Patient-Reported Outcomes)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Analgesic dose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thiol/Disulfide Homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effort duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cyst recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of the opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-operative pain at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative anesthetic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 75% MRR over weeks 1-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year freedom from biochemical failure (FFBF)
Endpoint domain: Mortality/survival
Primary endpoint: 10-year freedom from distant metastasis (FFDM)
Endpoint domain: Mortality/survival
Primary endpoint: 10-year cancer-specific survival (CSS)
Endpoint domain: Mortality/survival
Primary endpoint: desquamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bowel function deterioration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pelvic floor dysfunction impact on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in parent-reported SDB severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violent charges
Endpoint domain: Adverse events/effects
Primary endpoint: nonviolent charges
Endpoint domain: Adverse events/effects
Primary endpoint: IPV behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Contraceptive use by secondary participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: willingness for retreatment
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: incontinence episode frequency per 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exclusive breastfeeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall success of breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: T1/2 delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of lung fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of cardiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of pulmonary side effects
Endpoint domain: Adverse events/effects
Primary endpoint: sickness absences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) at 5 years in patients with tumor necrosis
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) at 5 years in patients with high hypoxia gene score
Endpoint domain: Mortality/survival
Primary endpoint: serum TRACP‐5b levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum TNF‐α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean volume voided
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence episodes/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased mortality associated with impaired BP recovery
Endpoint domain: Mortality/survival
Primary endpoint: Higher increases in ADAS-cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of SVR patients with completed records
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of follow‐up records
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxygen Saturation (SatO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PCS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of remaining free from VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of infantile atopic eczema at age 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CPR success score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compression rate at optimal depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of difficulty
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Reaction times of Stroop incongruent tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxy-Hb variations in left dorsolateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxy-Hb variations in right inferior frontal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: disability relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sufentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 2 or >RD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes